公开(公告)号：US20240352101A1

公开(公告)日：2024-10-24

申请号：US18403218

申请日：2024-01-03

Applicant: Duke University

Inventor： Edward F. Patz, JR. ,  Michael J. Campa ,  Elizabeth Gottlin ,  Barton F. Haynes ,  Hua-Xin Liao ,  M. Anthony Moody

IPC: C07K16/18 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K14/72 ,  C07K16/28 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/72 ,  G01N33/6872 ,  G01N33/6878 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/4716

Abstract: Disclosed herein are Complement factor H(CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

公开(公告)号：US20240317849A1

公开(公告)日：2024-09-26

申请号：US18257793

申请日：2021-12-20

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jason Mastaitis ,  Andrew J. Murphy ,  John McWhirter ,  Vera Voronina ,  Jesper Gromada

IPC: C07K16/26 ,  A01K67/0275 ,  C07K14/72 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC classification number: C07K16/26 ,  A01K67/0275 ,  C07K14/72 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  A01K2217/07 ,  A01K2227/105 ,  A01K2267/01 ,  C07K2317/56 ,  C07K2317/76 ,  C12N2310/20

Abstract: Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.

公开(公告)号：US20240067702A1

公开(公告)日：2024-02-29

申请号：US18039582

申请日：2021-12-02

Applicant: DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.

Inventor： Zhixiang PAN ,  Zhigan JIANG ,  Haiying HE ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: C07K14/72 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07K14/72 ,  A61P3/04 ,  A61P3/10 ,  A61K38/00

Abstract: A class of lactam-modified polypeptide compounds and the use thereof in the preparation of a drug for treating related diseases.

公开(公告)号：US11785922B2

公开(公告)日：2023-10-17

申请号：US16624575

申请日：2018-05-03

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Eun Ju Lee ,  Hyo-Soo Kim

IPC: C12N15/00 ,  C12N15/113 ,  C12N15/85 ,  C12N15/09 ,  A01K67/027 ,  C07K14/72 ,  C12N9/22

CPC classification number: A01K67/0275 ,  C07K14/72 ,  C12N9/22 ,  C12N15/113 ,  C12N15/8509 ,  A01K2217/07 ,  A01K2227/105 ,  C07K2319/09

Abstract: Provided are a protein complex in which estrogen receptor 2 (-ERT2) is fused to CRISPR associated protein 9 (Cas9), and a recombinant vector carrying a gene coding the protein complex, wherein ERT2 is bonded to the N-terminus and C-terminus of nuclear localization sequence (NLS)-removed Cas9 and the complex has the advantage of translocating from the cytosol into the nucleus at a certain time point upon treatment with tamoxifen and modifying a specific DNA with the aid of guide RNA (gRNA), ultimately enabling a more elaborate DNA modification operation in a desired part at a desired time point.

公开(公告)号：US20190233897A1

公开(公告)日：2019-08-01

申请号：US16122286

申请日：2018-09-05

Applicant: FOUNDATION MEDICINE, INC.

Inventor： Maureen T. Cronin ,  Garrett Michael Frampton ,  Doron Lipson ,  Vincent A. Miller ,  Gary Palmer ,  Jeffrey S. Ross ,  Philip James Stephens ,  Roman Yelensky

IPC: C12Q1/6886 ,  A61K31/675 ,  A61K31/4196 ,  A61K31/439 ,  A61K45/06 ,  A61K31/567 ,  A61K31/565 ,  A61K31/436 ,  A61K31/4439 ,  C07K16/28 ,  A61K31/416 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/472 ,  A61K31/536 ,  A61K31/5415 ,  C07K14/72

CPC classification number: C12Q1/6886 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/428 ,  A61K31/436 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/536 ,  A61K31/5415 ,  A61K31/565 ,  A61K31/567 ,  A61K31/675 ,  A61K45/06 ,  C07K14/72 ,  C07K16/2869 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

公开(公告)号：US20180251545A1

公开(公告)日：2018-09-06

申请号：US15972053

申请日：2018-05-04

Applicant: Regeneron Pharmaceutical, Inc.

Inventor： Jingtai CAO ,  Eunice CHEUNG ,  Ivan B. LOBOV

IPC: C07K16/28 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  C07K19/00 ,  A61K38/00 ,  C07K14/72

CPC classification number: C07K16/28 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K16/2869 ,  C07K19/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist such as an anti-APLNR antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (for example, aflibercept).

公开(公告)号：US20180057565A1

公开(公告)日：2018-03-01

申请号：US15582067

申请日：2017-04-28

Applicant: President and Fellows of Harvard College

Inventor： Rebecca Yue LIANG ,  Minyun ZHOU ,  Gregory L. VERDINE

IPC: C07K14/72 ,  A61K38/00

CPC classification number: C07K14/72 ,  A61K38/00

Abstract: Provided herein are stapled or stitched polypeptides comprising an alpha-helical segment, wherein the polypeptide binds to the insulin receptor, and wherein the peptide comprises at least two cross-linked amino acids as shown in Formula (iii), or at least three cross-linked amino acids as shown in Formula (iv). Further provided are pharmaceutical compositions comprising the stapled or stitched polypeptides, methods of use, e.g., methods of treating a diabetic condition or complications thereof. Precursor “unstapled” polypeptides useful in the preparation of stapled and stitched polypeptides are also described.

公开(公告)号：US20170304390A1

公开(公告)日：2017-10-26

申请号：US15595517

申请日：2017-05-15

Applicant: Novopyxis, Inc.

Inventor： Madhavi P. GAVINI ,  Raja R. SRINIVAS

IPC: A61K38/08 ,  A61K47/10 ,  A61K31/7088 ,  A61K48/00

CPC classification number: A61K38/08 ,  A01K2267/03 ,  A61K31/7088 ,  A61K47/10 ,  A61K48/005 ,  A61P3/06 ,  A61P3/10 ,  A61P9/12 ,  A61P13/12 ,  A61P25/28 ,  C07K7/06 ,  C07K14/72

Abstract: New polypeptide agonists of AT2R are disclosed, as well as pharmaceutical compositions comprising the agonists, methods of their use in the treatment of diseases, conditions or disorders characterized by insufficient AT2R activity or excessive AT1R activity, and methods of their use as laboratory reagents for research purposes.

公开(公告)号：US20170210800A1

公开(公告)日：2017-07-27

申请号：US15480199

申请日：2017-04-05

Applicant: Regeneron Pharmaceuticals, Inc

Inventor： Panayiotis Stevis ,  Andrew J. Murphy ,  Jesper Gromada ,  Yonaton Ray ,  Jee H. Kim ,  Ivan B. Lobov

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/46

CPC classification number: C07K16/28 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/64 ,  A61P9/08 ,  A61P9/10 ,  C07K14/47 ,  C07K14/705 ,  C07K14/72 ,  C07K16/2869 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

公开(公告)号：US20160267244A1

公开(公告)日：2016-09-15

申请号：US15159603

申请日：2016-05-19

Applicant: Samuel Bogoch ,  Elenore S. Bogoch ,  Anne-Elenore Bogoch Borsanyi ,  Samuel Winston Bogoch

Inventor： Samuel Bogoch ,  Elenore S. Bogoch ,  Anne-Elenore Bogoch Borsanyi ,  Samuel Winston Bogoch

IPC: G06F19/00

CPC classification number: C07K14/44 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/542 ,  A61K2039/552 ,  C07K14/005 ,  C07K14/72 ,  C12N2760/16122 ,  C12N2770/24122 ,  C12N2770/32022 ,  G16H50/30 ,  Y02A90/26

Abstract: The present invention provides methods of predicting the relative growth rate, replication rate, or lethality of a first malignancy as compared to another malignancy or as compared to a plurality of malignancies, including methods of predicting the relative growth rate, replication rate, or relative lethality of a primary malignancy as compared to a metastatic malignancy, including comparing the concentration of Replikin sequences in the first malignancy with the concentration of Replikin sequences in another malignancy or malignancies and further provides Replikin peptides and Replikin Peak Genes identified within a malignancy for diagnostic, therapeutic, preventive, and predictive purposes.

Abstract translation: 本发明提供了预测与其他恶性肿瘤相比的第一恶性肿瘤的相对生长率，复制率或致死率或与多种恶性肿瘤相比的方法，包括预测相对生长速率，复制率或相对致死率的方法 与转移性恶性肿瘤相比，包括将第一恶性肿瘤中的Replikin序列的浓度与另一恶性肿瘤或恶性肿瘤中的Replikin序列的浓度进行比较，并进一步提供在恶性肿瘤内鉴定的复制素肽和Replikin峰基因用于诊断，治疗 ，预防和预测目的。